Taking Diagnosis to a New Level
Pathology: The First Priority
At RPCI, a dedicated team of board-certified hematopathologists performs state-of-the-art, integrated diagnostic hematopathology—essential to diagnosing and classifying hematolymphoid neoplasms according to the most recent WHO classification.
Pathology is not just looking at cells under the microscope anymore. The integrated diagnostic approach is based on comprehensive clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic studies of blood, bone marrow and extramedullary tissue samples.—George Deeb, MD, Associate Professor of Oncology, Director of Hematopathology and Department of Pathology & Laboratory Medicine; Associate Director, Laboratory of Clinical Flow Cytometry.
Our hematopathologists work closely with the leukemia clinical team and other ancillary laboratories at RPCI to expedite prompt, comprehensive assessments. The ancillary laboratories incorporate the following:
- Bone marrow laboratory
- Immunohistochemistry laboratory with wide arrays of markers available
- Flow and image cytometry laboratory with a spectrum of comprehensive panels of markers to thoroughly characterize hematolymphoid neoplasms immunophenotypically
- Cytogenetic laboratory with karyotypic analysis and large number of FISH probes for many types of genetic abnormalities
- Molecular diagnostic laboratory with a plethora of PCR and sequencing-based analyses
Going with the Flow
RPCI’s Flow and Image Cytometry Facility—recognized as one of the nation’s first and finest—analyzes cell samples for RPCI clinicians and researchers, leading health centers and many National Institutes of Health clinical studies. This unique facility specializes in leukemias and lymphomas, identifying specific cancer types and subtypes by determining the specific antigen expression of the tumor, using analyses with antibodies and laser-activated flow cytometry.